Table 5.
Acylcarnitines C5, C10, C16, C18:1, and C18:2 levels (μg/L) with statistical significance according to the clinical presentation of CAD.
| CAD Groups | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| NSTEMI (α) | STEMI (β) | UA (γ) | SA (δ) | ||||||||||
| Median | ↓95.0% CIs | ↑95.0% CIs | Median | ↓95.0% CIs | ↑95.0% CIs | Median | ↓95.0% CIs | ↑95.0% CIs | Median | ↓95.0% CIs | ↑95.0% CIs |
* p (Pair) |
|
| C5 | 24.79 | 23.46 | 28.80 | 29.08 | 26.36 | 30.73 | 25.13 | 22.86 | 27.70 | 25.72 | 24.95 | 27.50 | 0.026 (δ–γ) |
| C10 | 89.88 | 78.25 | 105.42 | 86.53 | 79.36 | 94.45 | 91.50 | 83.49 | 110.42 | 106.09 | 96.74 | 116.37 | 0.019 (δ–β) |
| C16 | 58.38 | 55.03 | 63.64 | 58.29 | 55.82 | 60.89 | 62.90 | 60.82 | 66.52 | 63.21 | 60.85 | 65.63 | 0.012 (δ–β) |
| C18:1 | 85.82 | 78.64 | 94.91 | 82.80 | 76.43 | 88.61 | 91.30 | 79.31 | 97.06 | 92.53 | 88.15 | 97.76 | 0.013 (δ–β) |
| C18:2 | 54.86 | 50.74 | 59.54 | 50.26 | 47.34 | 52.41 | 53.75 | 50.00 | 60.48 | 60.21 | 57.89 | 63.29 | >0.001 (δ–β) |
* Kruskal–Wallis (pair) Bonferroni corrected.